Safety and effectiveness of intravitreal bevacizumab and ranibizumab injections for treatment of retinal disease patients: an observational study
- Conditions
- retinal diseases or conditions that can be treated with bevacizumab or ranibizumab such as neovascular age-related macular degeneration (neovascular AMD)retinal vein occlusion(RVO)related macular degeneration (neovascular AMD),diabetic macular edema (DME),diabetic macular edema (DME)and macular edeneovascular age-
- Registration Number
- TCTR20141002001
- Lead Sponsor
- Health Intervention and Technology Assessment Program (HITAP)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 6399
� Sign informed consent which was approved by the institutional review board (IRB)/ independent ethics committees (IECs) of each hospital.
� age ≥ 18 years of either gender.
� be patients with retinal diseases who are treated or will be treated (previously untreated) with IVB or IVR before participating in this study.
� no contraindication to IVB or IVR such as allergy to the active ingredient or their excipients.
� no condition of infection around or at the eyes before receiving IVR.
� can participate in the study for at least 6 months after the enrollment.
� have contraindication of bevacizumab or ranibizumab and their excipients
� switch between the investigational drugs within 6 months before the enrolment and during the 6-month of the study period
Data collection of any subjects will be terminated when
� switch between the investigational drugs during the follow up period
� subjects want to withdraw from the study
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method